Search Results for "Bepreve"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Bepreve. Results 1 to 3 of 3 total matches.
See also: bepotastine
In Brief: OTC Alcaftadine (Lastacaft Once Daily Relief) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
≥3 yrs Rx 35.00
Bepotastine – Bepreve (Bausch + Lomb) 1.5% soln* (5, 10 mL) 1 drop bid ≥2 yrs Rx ...
The ophthalmic H1-antihistamine alcaftadine 0.25%,
which has been available by prescription since 2011
for use in patients with allergic conjunctivitis, is now
available without a prescription as Lastacaft Once
Daily Relief (Allergan) for temporary relief of itchy eyes
due to pollen, ragweed, grass, animal hair, and dander
in adults and children ≥2 years old. It is the third
ophthalmic antihistamine to be approved for over-the-counter
(OTC) use (see Table 1).
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
Bepotastine – Bepreve (Bausch & Lomb) 1.5% soln* (5, 10 mL) 1 drop bid 2 yrs Rx 230.10
Cetirizine – Zerviate ...
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic conjunctivitis in patients ≥2
years old. Oral cetirizine (Zyrtec, and others), which is
used for treatment of allergic conjunctivitis and rhinitis,
has been available over the counter (OTC) for years.
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
not effective in
relieving erythema. Alcaftadine (Lastacaft), azelastine,
bepotastine (Bepreve), epinastine ...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 doi:10.58347/tml.2025.1725a | Show Introduction Hide Introduction